Shen Yeh-You, Shiau Yu-Chien, Wang Jhi-Joung, Ho Shung-Tai, Kao Chia-Hung
Department of Nuclear Medicine and PET Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Anticancer Res. 2002 Mar-Apr;22(2B):1257-64.
The purpose of this study was investigate the role of 18F-2deoxyglucose positron emission tomography (FDG-PET) in staging small cell lung cancer (SCLC), its efficacy for the discrimination of limited disease (LD) and extensive disease (ED) stages and its regional sensitivity for different metastatic locations. Twenty-five patients with histologically confirmed SCLC and 42 radiologically-staged tumor sites were retrospectively investigated. The LD sample included 10 patients while the ED included 15 patients. All of the 25 primary tumor sites (100%) were visualized and 41 out of 42 (97.6%) of the metastases could be identified, but FDG-PET was needed for anatomical localization. The efficacy of FDG-PET was studied in the staging of SCLC patients and compared with the initial staging of conventional modality findings. FDG-PET down-staged (from ED to LD) one case and up-staged (from LD to ED) one case of SCLC. In summary, all of the patients with ED were correctly staged by FDG-PET alone. We conclude that FDG-PET is a substantial tool in the staging work-up of SCLC if it is performed initially to allow fast identification of patients with extensive disease stages and thus saves additional radiological or invasive examinations. Our preliminary results support the usefulness of whole body FDG-PET for staging SCLC.
本研究的目的是探讨18F-2脱氧葡萄糖正电子发射断层扫描（FDG-PET）在小细胞肺癌（SCLC）分期中的作用、其对局限期（LD）和广泛期（ED）的鉴别效能以及对不同转移部位的区域敏感性。对25例经组织学确诊为SCLC的患者和42个经影像学分期的肿瘤部位进行了回顾性研究。LD组包括10例患者，ED组包括15例患者。25个原发肿瘤部位全部（100%）显影，42个转移灶中的41个（97.6%）可被识别，但需要FDG-PET进行解剖定位。研究了FDG-PET在SCLC患者分期中的效能，并与传统检查方法的初始分期进行比较。FDG-PET使1例SCLC患者分期降低（从ED降至LD），1例分期升高（从LD升至ED）。总之，所有ED患者仅通过FDG-PET就可正确分期。我们得出结论，如果最初进行FDG-PET检查以快速识别广泛期疾病患者，从而节省额外的影像学或侵入性检查，那么它是SCLC分期检查中的一项重要工具。我们的初步结果支持全身FDG-PET在SCLC分期中的实用性。
